Blood glucose monitor problems to be discussed at March 20-21 FDA panel meeting.
This article was originally published in The Tan Sheet
Executive Summary
BLOOD GLUCOSE MONITOR PROBLEMS SLATED FOR PANEL DISCUSSION at a March 20-21 meeting of FDA's Clinical Chemistry & Clinical Toxicology Devices Panel, according to an upcoming Federal Register notice. FDA is looking for input from the advisory panel and from public presentations by professional organizations, industry and consumers on "mechanisms to help minimize problems associated with" self-monitoring blood glucose systems. The meeting is scheduled to take place at the Holiday Inn in Gaithersburg, Md.